1887

Abstract

Since the successful use of vaccinia virus (VACV) in the immunization strategies to eliminate smallpox, research has been focused on the development of recombinant VACV strains expressing proteins from various pathogens. Attempts at decreasing the side effects associated with exposure to recombinant, wild-type viral strains have led to the development of attenuated viruses. Yet while these attenuated VACV’s have improved safety profiles compared to unmodified strains, their clinical use has been hindered due to efficacy issues in stimulating a host immune response. This deficiency has largely been attributed to decreased production of the target protein for immunization. Efforts to increase protein production from attenuated VACV strains has largely centered around modulation of viral factors, while manipulation of the translation of viral mRNAs has been largely unexplored. In this study we evaluate the use of translation enhancing element hTEE-658 to increase recombinant protein production in an attenuated VACV system. Optimization of the use of this motif is also attempted by combining it with strategies that have demonstrated effectiveness in previous research. We show that extension of the 5′ leader sequence containing hTEE-658 does not improve motif function, nor does the combination with other known translation enhancing elements. However, the sole use of hTEE-658 in an attenuated VACV system is shown to increase protein expression levels beyond those of a standard viral promoter when used with a wild-type virus. Taken together these results highlight the potential for hTEE-658 to improve the effectiveness of attenuated VACV vaccine candidates and give insights into the optimal sequence context for its use in vaccine design.

Funding
This study was supported by the:
  • Midwestern University (Award intramural funds)
    • Principle Award Recipient: BrianP. Wellensiek
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001624
2021-08-12
2024-10-03
Loading full text...

Full text loading...

/deliver/fulltext/jgv/102/8/jgv001624.html?itemId=/content/journal/jgv/10.1099/jgv.0.001624&mimeType=html&fmt=ahah

References

  1. Condit RC, Moussatche N, Traktman P. In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res 2006; 66:31–124 [View Article] [PubMed]
    [Google Scholar]
  2. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD et al. Vaccinia virus vaccines: Past, present and future. Antiviral Res 2009; 84:1–13 [View Article] [PubMed]
    [Google Scholar]
  3. Baxby D. The origins of vaccinia virus. J Infect Dis 1977; 136:453–455 [View Article] [PubMed]
    [Google Scholar]
  4. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 2011; 11:189–217
    [Google Scholar]
  5. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006; 24:7009–7022 [View Article] [PubMed]
    [Google Scholar]
  6. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188:217–232 [View Article] [PubMed]
    [Google Scholar]
  7. Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T et al. Improved NYVAC-based vaccine vectors. PLoS One 2011; 6:e25674 [View Article]
    [Google Scholar]
  8. Gómez CE, Perdiguero B, Sánchez-Corzo C, Sorzano COS, Esteban M. Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways. Viruses 2017; 10: [View Article]
    [Google Scholar]
  9. Di Pilato M, Mejías-Pérez E, Sorzano COS, Esteban M. Distinct roles of Vaccinia virus NF-κb inhibitor proteins A52, B15, and K7 in the immune response. J Virol 2017; 91: [View Article] [PubMed]
    [Google Scholar]
  10. Babendure JR, Babendure JL, Ding JH, Tsien RY. Control of mammalian translation by mRNA structure near caps. Rna 2006; 12:851–861 [View Article] [PubMed]
    [Google Scholar]
  11. Gray NK, Wickens M. Control of translation initiation in animals. Annu Rev Cell Dev Biol 1998; 14:399–458 [View Article]
    [Google Scholar]
  12. Kozak M. A short leader sequence impairs the fidelity of initiation by eukaryotic ribosomes. Gene Expr 1991; 1:111–115 [PubMed]
    [Google Scholar]
  13. Kozak M. Effects of long 5’ leader sequences on initiation by eukaryotic ribosomes in vitro. Gene Expr 1991; 1:117–125 [PubMed]
    [Google Scholar]
  14. Wellensiek BP, Larsen AC, Stephens B, Kukurba K, Waern K et al. Genome-wide profiling of human cap-independent translation-enhancing elements. Nat Methods 2013; 10:747–750 [View Article] [PubMed]
    [Google Scholar]
  15. Wellensiek BP, Larsen AC, Flores J, Jacobs BL, Chaput JC. A leader sequence capable of enhancing RNA expression and protein synthesis in mammalian cells. Protein Sci 2013; 22:1392–1398 [View Article] [PubMed]
    [Google Scholar]
  16. Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005; 294:2734–2743 [View Article] [PubMed]
    [Google Scholar]
  17. Maduro M. Random DNA sequence generator; 2015 http://www.faculty.ucr.edu/~mmaduro/random.htm
  18. Juba AN, Chaput JC, Wellensiek BP. Exploring the role of AUG triplets in human cap-independent translation enhancing elements. Biochemistry 2018; 57:6308–6318 [View Article] [PubMed]
    [Google Scholar]
  19. Expasy SIB Swiss Institute of Bioinformatics; 2015 https://web.expasy.org/translate
  20. Markham NR, Zuker M. UNAFold: software for nucleic acid folding and hybridization. Methods Mol Biol 2008; 453:3–31 [View Article] [PubMed]
    [Google Scholar]
  21. Jancovich JK, Chapman D, Hansen DT, Robida MD, Loskutov A et al. Immunization of pigs by DNA Prime and recombinant Vaccinia virus boost to identify and rank African Swine fever virus immunogenic and protective proteins. J Virol 2018; 92: [View Article]
    [Google Scholar]
  22. Ball LA. High-frequency homologous recombination in vaccinia virus DNA. J Virol 1987; 61:1788–1795 [View Article] [PubMed]
    [Google Scholar]
  23. Chappell SA, Edelman GM, Mauro VP. Biochemical and functional analysis of a 9-nt RNA sequence that affects translation efficiency in eukaryotic cells. Proc Natl Acad Sci U S A 2004; 101:9590–9594 [View Article] [PubMed]
    [Google Scholar]
  24. Kirshner ZZ, Gibbs RB. Use of the REVERT total protein stain as a loading control demonstrates significant benefits over the use of housekeeping proteins when analyzing brain homogenates by Western blot. Mol Cell Endocrinol 2018; 473:156–165 [View Article] [PubMed]
    [Google Scholar]
  25. Byrd CM, Hruby DE. Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus. Methods Mol Biol 2004; 269:31–40 [View Article] [PubMed]
    [Google Scholar]
  26. Gómez CE, Nájera JL, Jiménez V, Wagner R, Graf M et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007; 25:2863–2885 [View Article] [PubMed]
    [Google Scholar]
  27. Esposito J, Brechling K, Baer G, Moss B. Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies. Virus Genes 1987; 1:7–21 [View Article] [PubMed]
    [Google Scholar]
  28. Wang W, Huang B, Wang X, Tan W, Ruan L. Improving cross-protection against influenza virus using recombinant Vaccinia vaccine expressing NP and M2 ectodomain tandem repeats. Virol Sin 2019; 34:583–591 [View Article] [PubMed]
    [Google Scholar]
  29. Haddad D. Genetically engineered Vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery. Front Oncol 2017; 7:96 [View Article] [PubMed]
    [Google Scholar]
  30. Maki J, Guiot AL, Aubert M, Brochier B, Cliquet F et al. Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG®): a global review. Vet Res 2017; 48:57 [View Article] [PubMed]
    [Google Scholar]
  31. Sumner RP, Ren H, Ferguson BJ, Smith GL. Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators. Vaccine 2016; 34:4827–4834 [View Article] [PubMed]
    [Google Scholar]
  32. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 2003; 100:9458–9463 [View Article] [PubMed]
    [Google Scholar]
  33. Kozak M. Leader length and secondary structure modulate mRNA function under conditions of stress. Mol Cell Biol 1988; 8:2737–2744 [View Article] [PubMed]
    [Google Scholar]
  34. Bablanian R, Goswami SK, Esteban M, Banerjee AK, Merrick WC. Mechanism of selective translation of vaccinia virus mRNAs: differential role of poly(A) and initiation factors in the translation of viral and cellular mRNAs. J Virol 1991; 65:4449–4460 [View Article] [PubMed]
    [Google Scholar]
  35. Strnadova P, Ren H, Valentine R, Mazzon M, Sweeney TR et al. Inhibition of translation initiation by protein 169: A Vaccinia virus strategy to suppress innate and adaptive immunity and alter virus virulence. PLoS Pathog 2015; 11:e1005151 [View Article] [PubMed]
    [Google Scholar]
  36. Chu D, Barnes DJ, von der Haar T. The role of tRNA and ribosome competition in coupling the expression of different mRNAs in Saccharomyces cerevisiae. Nucleic Acids Res 2011; 39:6705–6714 [View Article] [PubMed]
    [Google Scholar]
  37. De Vos D, Bruggeman FJ, Westerhoff HV, Bakker BM. How molecular competition influences fluxes in gene expression networks. PLoS One 2011; 6:e28494 [View Article] [PubMed]
    [Google Scholar]
  38. Hebben M, Brants J, Birck C, Samama JP, Wasylyk B et al. High level protein expression in mammalian cells using a safe viral vector: Modified vaccinia virus Ankara. Protein Expr Purif 2007; 56:269–278 [View Article] [PubMed]
    [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.001624
Loading
/content/journal/jgv/10.1099/jgv.0.001624
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error